Boehringer throws basal insulin baby back to Lilly
This article was originally published in Scrip
Executive Summary
Lilly is to reassume the sole worldwide development and commercialization rights for the novel basal insulin analog, LY2605541, after partner, Boehringer Ingelheim, "elected to terminate that specific part of its collaboration with Lilly because of “independent strategic portfolio considerations". But the loss of its partner may cause Lilly, too, to reconsider the prospects of LY2605541.